Who is sponsoring NCT00418795?

NCT00418795 is sponsored by Zymenex A/S.

What drugs are being tested in NCT00418795?

Interventions in NCT00418795: recombinant human porphobilinogen deaminase (Porphozym).

What condition does NCT00418795 study?

NCT00418795 studies Acute Intermittent Porphyria.

Is NCT00418795 still recruiting?

NCT00418795 is currently completed. Last updated 9 March 2018.

Last reviewed 2018-03-09 · How we verify

NCT00418795

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Porphozym in the Treatment of Acute Attacks in AIP

Completed Phase 2, PHASE3 Last updated 9 March 2018

What this trial tests

Phase 2, PHASE3 trial testing recombinant human porphobilinogen deaminase (Porphozym) in Acute Intermittent Porphyria in 36 participants. Completed in 20 June 2006.

Timeline

11 June 2003

Primary endpoint
20 June 2006

20 June 2006

Quick facts

Lead sponsor	Zymenex A/S
Phase	Phase 2, PHASE3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	36
Start date	11 June 2003
Primary completion	20 June 2006
Estimated completion	20 June 2006
Sites	1 location across United States

Drugs / interventions tested

recombinant human porphobilinogen deaminase (Porphozym) — full drug profile →

Conditions studied

Acute Intermittent Porphyria — all drugs for Acute Intermittent Porphyria →

Sponsor

Zymenex A/S — full company profile →

Who can join

18 and older, any sex, with Acute Intermittent Porphyria. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A multi-centre, double-blind, randomized, placebo controlled, parallel group trial, investigating the efficacy and safety of Porphozym (recombinant human porphobilinogen deaminase)in the treatment of acute attacks in AIP.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Acute Intermittent Porphyria

Currently open trials in the same condition.

NCT01617642 — Dental Health, Diet, Inflammation and Biomarkers in Patients With Acute Intermittent Porphyria(AIP) · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00418795 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zymenex A/S
Last refreshed: 9 March 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00418795.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing